The Pistoia Alliance Conference in April 2011 included a series of 10-minute "lightning talks" from vendors about what they think pharma will look like in 2020. This presentation was delivered by John P. McAlister of CambridgeSoft.
The Pistoia Alliance: Update on Strategy and ProgressPistoia Alliance
Ramesh Durvasula, Pistoia Alliance board member, discusses the Pistoia Alliance mission and recaps activities in 2011-12, with particular emphasis on the successful completion of the Sequence Squeeze Competition and Sequence Services Phase 2. The presentation was delivered at BioITWorld in Boston in April 2012.
Emerging Life Sciences Collaboration on Common Service SpecificationPistoia Alliance
Presentation by Pistoia Alliance reps Ian Harrow (Pfizer) and Nick Lynch (AstraZeneca) at the International Conference on Trends for Scientific Information Professionals, October 2010.
Pablo Castro, inventor of the OData protocol at Microsoft, describes the application of OData to the management of life science data in a presentation delivered in an open meeting and webinar of the Pistoia Alliance Technical Committee.
The document discusses the challenges of complying with legislation controlling substances across different countries and regions. It describes the Controlled Substance Compliance Service (CSCS) project led by Pistoia Alliance to address this issue. The project defined requirements, issued a request for proposals, and selected two vendors - ChemAxon/Patcore and Scitegrity - to develop controlled substance identification solutions using different technologies. The project helped establish a need for such solutions and a community of experts to address the global controlled substance compliance problem.
The document discusses Affinity Therapeutics' technology platform for developing microparticle formulations that provide extended local release of antibiotics to prevent surgical site infections. The company was founded in 2010 and is developing formulations to be used with hernia mesh repairs initially, with the goal of licensing the technology to medical device companies. The company has received an NIH Phase I SBIR grant and is working to negotiate licensing and facility agreements with universities.
The Pistoia Alliance Conference in April 2011 included a series of 10-minute "lightning talks" from vendors about what they think pharma will look like in 2020. This presentation was delivered by John P. McAlister of CambridgeSoft.
The Pistoia Alliance: Update on Strategy and ProgressPistoia Alliance
Ramesh Durvasula, Pistoia Alliance board member, discusses the Pistoia Alliance mission and recaps activities in 2011-12, with particular emphasis on the successful completion of the Sequence Squeeze Competition and Sequence Services Phase 2. The presentation was delivered at BioITWorld in Boston in April 2012.
Emerging Life Sciences Collaboration on Common Service SpecificationPistoia Alliance
Presentation by Pistoia Alliance reps Ian Harrow (Pfizer) and Nick Lynch (AstraZeneca) at the International Conference on Trends for Scientific Information Professionals, October 2010.
Pablo Castro, inventor of the OData protocol at Microsoft, describes the application of OData to the management of life science data in a presentation delivered in an open meeting and webinar of the Pistoia Alliance Technical Committee.
The document discusses the challenges of complying with legislation controlling substances across different countries and regions. It describes the Controlled Substance Compliance Service (CSCS) project led by Pistoia Alliance to address this issue. The project defined requirements, issued a request for proposals, and selected two vendors - ChemAxon/Patcore and Scitegrity - to develop controlled substance identification solutions using different technologies. The project helped establish a need for such solutions and a community of experts to address the global controlled substance compliance problem.
The document discusses Affinity Therapeutics' technology platform for developing microparticle formulations that provide extended local release of antibiotics to prevent surgical site infections. The company was founded in 2010 and is developing formulations to be used with hernia mesh repairs initially, with the goal of licensing the technology to medical device companies. The company has received an NIH Phase I SBIR grant and is working to negotiate licensing and facility agreements with universities.
This document discusses precompetitive collaborations in the pharmaceutical industry. It defines precompetitive as referring to standards, data, or processes that are common across an industry and provide no competitive advantage. The document outlines a precompetitive mission statement to foster collaborations between organizations to develop standards, identify partnerships, and transfer technology. It also describes current working groups focused on areas like biomarkers, clinical trial design, and data standards.
The Pistoia Alliance Biology Domain Strategy April 2011Pistoia Alliance
Michael Braxenthaler (Roche and external liaison officer for Pistoia) describes the Pistoia Alliance biology domain strategy at the first Pistoia Alliance Conference in April 2011.
The document discusses Lundbeck's use of open source software in pharmaceutical research and informatics. It describes how Lundbeck uses open source tools like Linux, Ruby on Rails, and GNU Scientific Library to build its in-house research platform LSP. It also discusses Lundbeck's involvement in pre-competitive collaborations through initiatives like Pistoia Alliance and IMI, which aim to improve data sharing and interoperability through open source solutions. The document advocates for more use of open standards and semantic technologies to better integrate diverse data sources and enable collaborative research.
The document discusses the HealthTIES program, an EU-funded initiative to support regional innovation ecosystems in health. It provides context on relevant science and innovation roadmaps and frameworks. The HealthTIES approach involves modeling regional health innovation systems, gathering data on inputs and outputs, benchmarking regions, and developing joint action plans. The program aims to strengthen regions' capacities in life sciences and medical technologies through improved collaboration between research institutions and industry.
Karen Arts is one of the founding members and chair of the board of directors of the Network of Networks, a not for profit organization, which aims to share best practices and establish national standards for clinical research conduct in Canada. For more info goto: http://n2canada.ca/
Pistoia presentation bio it-worldexpo 21april2010Nick Lynch
The document summarizes the origins and operations of the Pistoia Alliance, a non-profit organization formed to facilitate pre-competitive collaboration in the life sciences industry. The Pistoia Alliance was formed in Pistoia, Italy by GSK, AZ, Pfizer and Novartis to address common challenges with data interchange. Its mission is to standardize data exchange to reduce costs. Current projects include developing standards for semantic enrichment of literature, sequence data services, and electronic lab notebook queries. The organization has over 30 members and operates working groups to develop open standards through a governance process.
Boosting drug development through public private partnerships (Laverty OECD P...Per Koch
Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
The Pistoia Alliance Information Ecosystem WorkshopPistoia Alliance
Michael Braxenthaler, president of the Pistoia Alliance, introduces the concept of the information ecosystem in life science research and discusses the role the Pistoia Alliance can play within this ecosystem. The workshop occurred in October 2011.
Opening up pharmacological space, the OPEN PHACTs apiChris Evelo
The document provides an overview of the Open PHACTS project, which aims to create an open pharmacological space (OPS) through semantic integration of public drug discovery resources. It discusses the challenges of accessing and integrating scientific data across organizational boundaries. Open PHACTS builds a service layer and applications to allow standardized access and analysis of data from various public sources. It is a collaborative project involving academic and industry partners seeking to make pre-competitive drug discovery data more accessible and useful through semantic integration and common standards.
The document discusses online resources that can support open drug discovery systems. It outlines how pharmaceutical companies spend billions annually on R&D and how public domain data from sources like literature, patents and databases could provide high value. However, such data is difficult to integrate and navigate due to a lack of standards and interoperability between sources. The Open PHACTS project aims to address this by developing standards to semantically integrate drug discovery data from public and private sources.
Access the webinar: http://goo.gl/p08pTz
These slides were presented in a webinar by Denodo in collaboration with BioStorage Technologies and Indiana Clinical and Translational Sciences Institute and Regenstrief Institute.
BioStorage Technologies, Inc., Indiana Clinical and Translational Sciences Institute, and Regenstrief Institute (CTSI) have joined Denodo to talk about the important role of technological advancements, such as data virtualization, in advancing biospecimen research.
By watching this webinar, you can gain insight into best practices around the integration of biospecimen and research data as well as technology solutions that provide consolidated views and rapid conversions of this data into valuable business insights. You will also learn how data virtualization can assist with the integration of data residing in heterogeneous repositories and can securely deliver aggregated data in real-time.
This document provides an overview of open innovation. It begins with introducing the speakers and goals of discussing open innovation without hype, exploring key themes practically, and sharing case studies and exercises. The topics to be covered include definitions of open innovation, benefits for organizations, differences between large and small companies, the ideal open innovation ecosystem, and a collaboration exercise. Overall, the document aims to provide insights into open innovation from life science and IT sectors through mixing presentations and group activities.
Acs collaborative computational technologies for biomedical research an enabl...Sean Ekins
This document discusses enabling more open and collaborative approaches to drug discovery through computational technologies. It argues that pre-competitive data sharing could help integrate historical knowledge and deliver high value. Open drug discovery may be a better approach than the traditional closed model. Tools and open interfaces could facilitate more open collaboration between different sectors involved in biomedical research. Mobile apps may help scientists access and share data more easily. Crowdsourcing approaches could engage more contributors to knowledge bases.
Collaborative Drug Discovery provides three key services:
1. CDD Vault for securely storing private data.
2. CDD Collaborate for selectively sharing subsets of private data with collaborators.
3. CDD Public, containing over 3 million compounds for public searching and data analysis.
The document outlines four collaborations using CDD to facilitate data and model sharing between academic and industry partners to further tuberculosis drug discovery. It argues that greater adoption of open data sharing and collaborative platforms could help address inefficiencies in the drug discovery process.
Fairification experience clarifying the semantics of data matricesPistoia Alliance
This webinar presents the Statistics Ontology, STATO which is a semantic framework to support the creation of standardized analysis reports to help with review of results in the form of data matrices. STATO includes a hierarchy of classes and a vocabulary for annotating statistical methods used in life, natural and biomedical sciences investigations, text mining and statistical analyses.
This webinar discusses driving adoption of microphysiological systems (MPS) in drug R&D. The webinar agenda includes presentations on multi-organ chips for safety and efficacy assessment from TissUse, current applications and future perspectives of organ-on-chips in pharmaceutical industry from AstraZeneca, and driving adoption of MPS from ToxRox Consulting. A panel discussion will be moderated by Mary Ellen Cosenza. The presentations will cover benefits of MPS for reducing drug failures and animal testing, applications across drug discovery and development, challenges for adoption, and perspectives from industry.
More Related Content
Similar to Introduction to Pistoia Alliance Annual Conference
This document discusses precompetitive collaborations in the pharmaceutical industry. It defines precompetitive as referring to standards, data, or processes that are common across an industry and provide no competitive advantage. The document outlines a precompetitive mission statement to foster collaborations between organizations to develop standards, identify partnerships, and transfer technology. It also describes current working groups focused on areas like biomarkers, clinical trial design, and data standards.
The Pistoia Alliance Biology Domain Strategy April 2011Pistoia Alliance
Michael Braxenthaler (Roche and external liaison officer for Pistoia) describes the Pistoia Alliance biology domain strategy at the first Pistoia Alliance Conference in April 2011.
The document discusses Lundbeck's use of open source software in pharmaceutical research and informatics. It describes how Lundbeck uses open source tools like Linux, Ruby on Rails, and GNU Scientific Library to build its in-house research platform LSP. It also discusses Lundbeck's involvement in pre-competitive collaborations through initiatives like Pistoia Alliance and IMI, which aim to improve data sharing and interoperability through open source solutions. The document advocates for more use of open standards and semantic technologies to better integrate diverse data sources and enable collaborative research.
The document discusses the HealthTIES program, an EU-funded initiative to support regional innovation ecosystems in health. It provides context on relevant science and innovation roadmaps and frameworks. The HealthTIES approach involves modeling regional health innovation systems, gathering data on inputs and outputs, benchmarking regions, and developing joint action plans. The program aims to strengthen regions' capacities in life sciences and medical technologies through improved collaboration between research institutions and industry.
Karen Arts is one of the founding members and chair of the board of directors of the Network of Networks, a not for profit organization, which aims to share best practices and establish national standards for clinical research conduct in Canada. For more info goto: http://n2canada.ca/
Pistoia presentation bio it-worldexpo 21april2010Nick Lynch
The document summarizes the origins and operations of the Pistoia Alliance, a non-profit organization formed to facilitate pre-competitive collaboration in the life sciences industry. The Pistoia Alliance was formed in Pistoia, Italy by GSK, AZ, Pfizer and Novartis to address common challenges with data interchange. Its mission is to standardize data exchange to reduce costs. Current projects include developing standards for semantic enrichment of literature, sequence data services, and electronic lab notebook queries. The organization has over 30 members and operates working groups to develop open standards through a governance process.
Boosting drug development through public private partnerships (Laverty OECD P...Per Koch
Presentation from the conference Science diplomacy in action Governance for international science co-operation: the example of Health Research 11-12 February, 2013, arranged by the French and British embassies as a follow up to the OECD STIG project, see http://beyondstig.oecd.org
The Pistoia Alliance Information Ecosystem WorkshopPistoia Alliance
Michael Braxenthaler, president of the Pistoia Alliance, introduces the concept of the information ecosystem in life science research and discusses the role the Pistoia Alliance can play within this ecosystem. The workshop occurred in October 2011.
Opening up pharmacological space, the OPEN PHACTs apiChris Evelo
The document provides an overview of the Open PHACTS project, which aims to create an open pharmacological space (OPS) through semantic integration of public drug discovery resources. It discusses the challenges of accessing and integrating scientific data across organizational boundaries. Open PHACTS builds a service layer and applications to allow standardized access and analysis of data from various public sources. It is a collaborative project involving academic and industry partners seeking to make pre-competitive drug discovery data more accessible and useful through semantic integration and common standards.
The document discusses online resources that can support open drug discovery systems. It outlines how pharmaceutical companies spend billions annually on R&D and how public domain data from sources like literature, patents and databases could provide high value. However, such data is difficult to integrate and navigate due to a lack of standards and interoperability between sources. The Open PHACTS project aims to address this by developing standards to semantically integrate drug discovery data from public and private sources.
Access the webinar: http://goo.gl/p08pTz
These slides were presented in a webinar by Denodo in collaboration with BioStorage Technologies and Indiana Clinical and Translational Sciences Institute and Regenstrief Institute.
BioStorage Technologies, Inc., Indiana Clinical and Translational Sciences Institute, and Regenstrief Institute (CTSI) have joined Denodo to talk about the important role of technological advancements, such as data virtualization, in advancing biospecimen research.
By watching this webinar, you can gain insight into best practices around the integration of biospecimen and research data as well as technology solutions that provide consolidated views and rapid conversions of this data into valuable business insights. You will also learn how data virtualization can assist with the integration of data residing in heterogeneous repositories and can securely deliver aggregated data in real-time.
This document provides an overview of open innovation. It begins with introducing the speakers and goals of discussing open innovation without hype, exploring key themes practically, and sharing case studies and exercises. The topics to be covered include definitions of open innovation, benefits for organizations, differences between large and small companies, the ideal open innovation ecosystem, and a collaboration exercise. Overall, the document aims to provide insights into open innovation from life science and IT sectors through mixing presentations and group activities.
Acs collaborative computational technologies for biomedical research an enabl...Sean Ekins
This document discusses enabling more open and collaborative approaches to drug discovery through computational technologies. It argues that pre-competitive data sharing could help integrate historical knowledge and deliver high value. Open drug discovery may be a better approach than the traditional closed model. Tools and open interfaces could facilitate more open collaboration between different sectors involved in biomedical research. Mobile apps may help scientists access and share data more easily. Crowdsourcing approaches could engage more contributors to knowledge bases.
Collaborative Drug Discovery provides three key services:
1. CDD Vault for securely storing private data.
2. CDD Collaborate for selectively sharing subsets of private data with collaborators.
3. CDD Public, containing over 3 million compounds for public searching and data analysis.
The document outlines four collaborations using CDD to facilitate data and model sharing between academic and industry partners to further tuberculosis drug discovery. It argues that greater adoption of open data sharing and collaborative platforms could help address inefficiencies in the drug discovery process.
Fairification experience clarifying the semantics of data matricesPistoia Alliance
This webinar presents the Statistics Ontology, STATO which is a semantic framework to support the creation of standardized analysis reports to help with review of results in the form of data matrices. STATO includes a hierarchy of classes and a vocabulary for annotating statistical methods used in life, natural and biomedical sciences investigations, text mining and statistical analyses.
This webinar discusses driving adoption of microphysiological systems (MPS) in drug R&D. The webinar agenda includes presentations on multi-organ chips for safety and efficacy assessment from TissUse, current applications and future perspectives of organ-on-chips in pharmaceutical industry from AstraZeneca, and driving adoption of MPS from ToxRox Consulting. A panel discussion will be moderated by Mary Ellen Cosenza. The presentations will cover benefits of MPS for reducing drug failures and animal testing, applications across drug discovery and development, challenges for adoption, and perspectives from industry.
Federated Learning (FL) is a learning paradigm that enables collaborative learning without centralizing datasets. In this webinar, NVIDIA present the concept of FL and discuss how it can help overcome some of the barriers seen in the development of AI-based solutions for pharma, genomics and healthcare. Following the presentation, the panel debate on other elements that could drive the adoption of digital approaches more widely and help answer currently intractable science and business questions.
It seems that AI is also becoming a buzzword, like design thinking. Everyone is talking about AI or wants to have AI, and sees all the ideas and benefits – that’s fine, but how do you get started? But what’s different now? Three innovations have finally put AI on the fast track: Big Data, with the internet and sensors everywhere; massive computing power, especially through the Cloud; and the development of breakthrough algorithms, so computers can be trained to accomplish more sophisticated tasks on their own with deep learning. If you use new technology, you need to explore and know what’s possible. With design thinking, it aids to outline the steps and define the ways in which you’re going to create the solution. Starting with mapping the customer journey, defining who will be using that service enhanced with intelligent technology, or who will benefit and gain value from it. We discuss how these two worlds are coming together, and how you get started to transform your venture with Artificial Intelligence using Design Thinking.
Speaker: Claudio Mirti, Principal Solution Specialist – Data & AI, Microsoft
Themes and objectives:
To position FAIR as a key enabler to automate and accelerate R&D process workflows
FAIR Implementation within the context of a use case
Grounded in precise outcomes (e.g. faster and bigger science / more reuse of data to enhance value / increased ability to share data for collaboration and partnership)
To make data actionable through FAIR interoperability
Speakers:
Mathew Woodwark,Head of Data Infrastructure and Tools, Data Science & AI, AstraZeneca
Erik Schultes, International Science Coordinator, GO-FAIR
Georges Heiter, Founder & CEO, Databiology
Knowledge graphs ilaria maresi the hyve 23apr2020Pistoia Alliance
Data for drug discovery and healthcare is often trapped in silos which hampers effective interpretation and reuse. To remedy this, such data needs to be linked both internally and to external sources to make a FAIR data landscape which can power semantic models and knowledge graphs.
2020.04.07 automated molecular design and the bradshaw platform webinarPistoia Alliance
This presentation described how data-driven chemoinformatics methods may automate much of what has historically been done by a medicinal chemist. It explored what is reasonable to expect “AI” approaches might achieve, and what is best left with a human expert. The implications of automation for the human-machine interface were explored and illustrated with examples from Bradshaw, GSK’s experimental automated design environment.
This presentation reviewed the challenges in identifying, acquiring and utilizing research data in relation to an evolving data market. Strategic solutions were examined in which the FAIR principles play a key role in the future of data management.
Dr. Dennis Wang discusses possible ways to enable ML methods to be more powerful for discovery and to reduce ambiguity within translational medicine, allowing data-informed decision-making to deliver the next generation of diagnostics and therapeutics to patients quicker, at lowered costs, and at scale.
The talk by Dr. Dennis Wang was followed by a panel discussion with Mr. Albert Wang, M. Eng., Head, IT Business Partner, Translational Research & Technologies, Bristol-Myers Squibb.
With the explosion of interest in both enhanced knowledge management and open science, the past few years have seen considerable discussion about making scientific data “FAIR” — findable, accessible, interoperable, and reusable. The problem is that most scientific datasets are not FAIR. When left to their own devices, scientists do an absolutely terrible job creating the metadata that describe the experimental datasets that make their way in online repositories. The lack of standardization makes it extremely difficult for other investigators to locate relevant datasets, to re-analyse them, and to integrate those datasets with other data. The Center for Expanded Data Annotation and Retrieval (CEDAR) has the goal of enhancing the authoring of experimental metadata to make online datasets more useful to the scientific community. The CEDAR work bench for metadata management will be presented in this webinar. CEDAR illustrates the importance of semantic technology to driving open science. It also demonstrates a means for simplifying access to scientific data sets and enhancing the reuse of the data to drive new discoveries.
Open interoperability standards, tools and services at EMBL-EBIPistoia Alliance
In this webinar Dr Henriette Harmse from EMBL-EBI presents how they are using their ontology services at EMBL-EBI to scale up the annotation of data and deliver added value through ontologies and semantics to their users.
Fair webinar, Ted slater: progress towards commercial fair data products and ...Pistoia Alliance
Elsevier is a global information analytics business that helps institutions and professional’s
advance healthcare and open science to improve performance for the benefit of humanity.
In this webinar, we discuss how Elsevier is increasingly leveraging the FAIR Guiding Principles to improve its products and services to better serve the scientific community.
Application of recently developed FAIR metrics to the ELIXIR Core Data ResourcesPistoia Alliance
The FAIR (Findable, Accessible, Interoperable and Reusable) principles aim to maximize the discovery and reuse of digital resources. Using recently developed software and metrics to assess FAIRness and supported through an ELIXIR Implementation Study, Michel worked with a subset of ELIXIR Core Data Resources to apply these technologies. In this webinar, he will discuss their approach, findings, and lessons learned towards the understanding and promotion of the FAIR principles.
Implementing Blockchain applications in healthcarePistoia Alliance
Blockchain technology can revolutionise the way information is exchanged between parties by bringing an unprecedented level of security and trust to these transactions. The technology is finding its way into multiple use cases but we are yet to see full adoption and real-world business implementation in the Healthcare industry.
In this webinar we will explore the main challenges and considerations for the implementation of Blockchain technology in Healthcare use cases. This is the third webinar in our Blockchain Education series.
Building trust and accountability - the role User Experience design can play ...Pistoia Alliance
In this webinar our panel of UX specialists give a brief introduction to User Experience before presenting the design opportunities UX can bring to AI. We all know that AI has great potential but has some significant hurdles to overcome not least so the human aspect of trust and ethical considerations when designing in the life sciences.
This document summarizes a webinar on using machine learning and data mining techniques to predict drug repurposing opportunities for chronic pancreatitis. Specifically:
1. Ensemble learning techniques like kernel-based models were used to analyze drug and disease target interaction data from multiple sources to identify potential drug candidates for repurposing.
2. The top 5 repurposing candidates identified through this process were being evaluated further by the partner organization Mission-Cure with the goal of beginning patient trials by January 2020.
3. Additional techniques discussed included using compressed sensing to analyze drug-disease networks and predict side effects to help evaluate candidate drugs identified for repurposing opportunities.
PA webinar on benefits & costs of FAIR implementation in life sciences Pistoia Alliance
The slides from the Pistoia Alliance Debates Webinar where a panel of experts from technology support providers and the biopharma industry, who have been invited to share their views on the "Benefits and costs of FAIR Implementation for life science industry".
Creating novel drugs is an extraordinarily hard and complex problem.
One of the many challenges in drug design is the sheer size of the search space for novel chemical compounds. Scientists need to find molecules that are active toward a biological target or pathway and at the same time have acceptable ADMET properties.
There is now considerable research going on using various AI and ML approaches to tackle these challenges.
Our distinguished speakers, Drs. Alex Tropsha and Ola Engkvist, will discuss their recent work in Drug Design involving Deep Reinforcement Learning and Neural Networks, and will answer questions from the audience on the current state of the research in the field.
Speakers:
Prof Alex Tropsha, Professor at University of North Carolina at Chapel Hill, USA
Dr. Ola Engkvist, Associate Director at AstraZeneca R&D, Gothenburg, Sweden
Alexander Tropsha presented on using AI and machine learning for drug design and discovery. He discussed using QSAR models to predict properties and activity of molecules based on their structural descriptors. He also introduced ReLeaSE, a new method using deep reinforcement learning to generate novel drug-like molecules and guide chemical library design through a thought cycle of molecule generation, model building, and iterative improvement. If successful, this approach could disrupt traditional computational drug discovery pipelines.
Project Management Semester Long Project - Acuityjpupo2018
Acuity is an innovative learning app designed to transform the way you engage with knowledge. Powered by AI technology, Acuity takes complex topics and distills them into concise, interactive summaries that are easy to read & understand. Whether you're exploring the depths of quantum mechanics or seeking insight into historical events, Acuity provides the key information you need without the burden of lengthy texts.
Skybuffer SAM4U tool for SAP license adoptionTatiana Kojar
Manage and optimize your license adoption and consumption with SAM4U, an SAP free customer software asset management tool.
SAM4U, an SAP complimentary software asset management tool for customers, delivers a detailed and well-structured overview of license inventory and usage with a user-friendly interface. We offer a hosted, cost-effective, and performance-optimized SAM4U setup in the Skybuffer Cloud environment. You retain ownership of the system and data, while we manage the ABAP 7.58 infrastructure, ensuring fixed Total Cost of Ownership (TCO) and exceptional services through the SAP Fiori interface.
Introduction of Cybersecurity with OSS at Code Europe 2024Hiroshi SHIBATA
I develop the Ruby programming language, RubyGems, and Bundler, which are package managers for Ruby. Today, I will introduce how to enhance the security of your application using open-source software (OSS) examples from Ruby and RubyGems.
The first topic is CVE (Common Vulnerabilities and Exposures). I have published CVEs many times. But what exactly is a CVE? I'll provide a basic understanding of CVEs and explain how to detect and handle vulnerabilities in OSS.
Next, let's discuss package managers. Package managers play a critical role in the OSS ecosystem. I'll explain how to manage library dependencies in your application.
I'll share insights into how the Ruby and RubyGems core team works to keep our ecosystem safe. By the end of this talk, you'll have a better understanding of how to safeguard your code.
How to Interpret Trends in the Kalyan Rajdhani Mix Chart.pdfChart Kalyan
A Mix Chart displays historical data of numbers in a graphical or tabular form. The Kalyan Rajdhani Mix Chart specifically shows the results of a sequence of numbers over different periods.
Building Production Ready Search Pipelines with Spark and MilvusZilliz
Spark is the widely used ETL tool for processing, indexing and ingesting data to serving stack for search. Milvus is the production-ready open-source vector database. In this talk we will show how to use Spark to process unstructured data to extract vector representations, and push the vectors to Milvus vector database for search serving.
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
OpenID AuthZEN Interop Read Out - AuthorizationDavid Brossard
During Identiverse 2024 and EIC 2024, members of the OpenID AuthZEN WG got together and demoed their authorization endpoints conforming to the AuthZEN API
Fueling AI with Great Data with Airbyte WebinarZilliz
This talk will focus on how to collect data from a variety of sources, leveraging this data for RAG and other GenAI use cases, and finally charting your course to productionalization.
How to Get CNIC Information System with Paksim Ga.pptxdanishmna97
Pakdata Cf is a groundbreaking system designed to streamline and facilitate access to CNIC information. This innovative platform leverages advanced technology to provide users with efficient and secure access to their CNIC details.
Threats to mobile devices are more prevalent and increasing in scope and complexity. Users of mobile devices desire to take full advantage of the features
available on those devices, but many of the features provide convenience and capability but sacrifice security. This best practices guide outlines steps the users can take to better protect personal devices and information.
Ocean lotus Threat actors project by John Sitima 2024 (1).pptxSitimaJohn
Ocean Lotus cyber threat actors represent a sophisticated, persistent, and politically motivated group that poses a significant risk to organizations and individuals in the Southeast Asian region. Their continuous evolution and adaptability underscore the need for robust cybersecurity measures and international cooperation to identify and mitigate the threats posed by such advanced persistent threat groups.
Generating privacy-protected synthetic data using Secludy and MilvusZilliz
During this demo, the founders of Secludy will demonstrate how their system utilizes Milvus to store and manipulate embeddings for generating privacy-protected synthetic data. Their approach not only maintains the confidentiality of the original data but also enhances the utility and scalability of LLMs under privacy constraints. Attendees, including machine learning engineers, data scientists, and data managers, will witness first-hand how Secludy's integration with Milvus empowers organizations to harness the power of LLMs securely and efficiently.
Main news related to the CCS TSI 2023 (2023/1695)Jakub Marek
An English 🇬🇧 translation of a presentation to the speech I gave about the main changes brought by CCS TSI 2023 at the biggest Czech conference on Communications and signalling systems on Railways, which was held in Clarion Hotel Olomouc from 7th to 9th November 2023 (konferenceszt.cz). Attended by around 500 participants and 200 on-line followers.
The original Czech 🇨🇿 version of the presentation can be found here: https://www.slideshare.net/slideshow/hlavni-novinky-souvisejici-s-ccs-tsi-2023-2023-1695/269688092 .
The videorecording (in Czech) from the presentation is available here: https://youtu.be/WzjJWm4IyPk?si=SImb06tuXGb30BEH .
UiPath Test Automation using UiPath Test Suite series, part 6DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 6. In this session, we will cover Test Automation with generative AI and Open AI.
UiPath Test Automation with generative AI and Open AI webinar offers an in-depth exploration of leveraging cutting-edge technologies for test automation within the UiPath platform. Attendees will delve into the integration of generative AI, a test automation solution, with Open AI advanced natural language processing capabilities.
Throughout the session, participants will discover how this synergy empowers testers to automate repetitive tasks, enhance testing accuracy, and expedite the software testing life cycle. Topics covered include the seamless integration process, practical use cases, and the benefits of harnessing AI-driven automation for UiPath testing initiatives. By attending this webinar, testers, and automation professionals can gain valuable insights into harnessing the power of AI to optimize their test automation workflows within the UiPath ecosystem, ultimately driving efficiency and quality in software development processes.
What will you get from this session?
1. Insights into integrating generative AI.
2. Understanding how this integration enhances test automation within the UiPath platform
3. Practical demonstrations
4. Exploration of real-world use cases illustrating the benefits of AI-driven test automation for UiPath
Topics covered:
What is generative AI
Test Automation with generative AI and Open AI.
UiPath integration with generative AI
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
3. Thanks!
Joe Donahue
Andreas Matern
Barbara Love
4. Thanks!
John Wise (Exec Director)
Deb Ausman (Communications)
Martyn Wilkins (Secretary)
Nick Lynch (External Liaison)
Ashley George (Treasurer)
5. Thanks!
Simon Thornber (GSK)
Sandor Szalma (Janssen)
David Kniaz (Merck)
Alex Drijver (ChemAxon)
Ramesh Durvasula (BMS)
Sean Ekins (CDD)
David Klatte (Pfizer)
Etzard Stolte, Ralph Schlapbach (HP)
Nick Trigg (Constellation Technologies)
Misha Kapushesky (Genestack)
William Spooner (Eagle Genomics)
Carl Chesal (Cycle Computing)
6. What you can expect today…
Delivery
• Sequence Services
– Overview (Simon Thornber)
– Presentations
– Demos
• HP
• Constellation Technologies/Genestack
• Eagle Genomics/Cycle Computing
• SequenceSqueeze Competition
7. What you can expect today…
Looking Forward:
Six New Pistoia Activities
• Dragon’s Den pitches
• Speed dating
8. The Pistoia Alliance – Setting The Stage
“Partnerships, integration and working
together are increasingly key themes in any
discussion about healthcare,
with the growing realization that no one
industry, organization, sector or service can
afford to go it alone, either financially or
practically.”
Source: PME (Pharmaceutical Market Europe) Nov 2011, www.pmlive.com
9. Rapidly Evolving Pharmaceutical Ecosystem
Proprietary
content
Public provider
content
provider
Big Life CRO Patient
Science organization
Company Pharma
Regulatory
authorities
Academic
group
Service provider
Software vendor
10. The Pistoia Mission
Lowering the barriers to
innovation
by improving inter-operability of
R&D business processes
through pre-competitive
collaboration
10
11. Role of the Pistoia Alliance
• Standards: Landscape, gaps, sign-posting, agile
standards development
• Fostering the market place for shared services
– Example: Sequence Services Project
• Open innovation
– Example: SequenceSqueeze Competition
• Platform for collaborative projects with defined legal
and financial framework